An Open-Label, Multi-Center Trial to Examine the Long Term Safety, Efficacy and Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease who have Failed Tapering of Corticosteroids